TSC-100 and TSC-101 are the Company's two lead TCR-T therapy candidates for the treatment of heme malignancies.
TScan has developed two lead TCR-T therapy candidates, TSC-100 and TSC-101, that target minor histocompatibility antigens HA-1 and HA-2, respectively.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2024 | $12.00 | Buy | BTIG Research |
| 5/13/2024 | $11.00 | Buy | Needham |
| 6/22/2023 | $8.00 | Outperform | Wedbush |
| 12/16/2021 | $21.00 | Buy | HC Wainwright & Co. |
| 8/13/2021 | Outperform | Cowen & Co. | |
| 8/10/2021 | $22.00 | Overweight | Barclays |
| 8/10/2021 | $22.00 | Overweight | Morgan Stanley |
| 8/10/2021 | $21.00 | Buy | Jefferies |
4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)
SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)
SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)
FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026 WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T
WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization. "We are excited to welcome Chrystal to TScan at this critical time as we continue to progress both clinical-stage programs in heme malignancies and solid tumors
WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development. Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry. "We are pleased to welcome Dawn to TScan at such an exciting time in the Company's evolution," said Debora Barton, M.D., Chief Medical Officer. "Her expertise in cell and gene therapy clinical
Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10th at 8:00 a.m. ET to discuss clinical updates from the ALLOHA Phase 1 trial and heme development strategy On track to dose first patient with multiplex TCR-T therapy and will provide an update on our Phase 1 study by the end of the year Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-sta
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually. Poster Presentation Details: Title: Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid TumorsAuthors: Rutuja Kulkarni, Akshat Sharma, Vivin Karthik, Kenneth L Jahan, Rakshi Bala, Nicolas G
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference; the fireside chat will be held at the New York Marriott Marquis on Thursday, September 5, 2024 at 8:30 a.m. ETH.C. Wainwright 26th Annual Global Investment Conference; the presentation will be held at the Lotte New York Palace Hotel on Tuesday, September 10, 2024 at 9:00 a.m. ET W
8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
144 - TScan Therapeutics, Inc. (0001783328) (Subject)
All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS is relapse-free for over one year following treatment with TSC-101 Patient with AML converted from detectable to undetectable disease following treatment with TSC-101 Data presented at TANDEM meeting suggests complete donor chimerism is an early indicator of treatment success Company to host virtual KOL event today, Monday, February 26, at 8:00 a.m. ET, to discuss the data presented at the 2024 Tandem Meetings WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- TScan Th
Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and is eligible t
Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and i
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 3 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 1 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.43, with a high estimate of $15.00 and a low estimate of $9.00. This upward trend is evident, with the current avera
HC Wainwright & Co. analyst Andrew Fein reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $15 price target.
TSC-100 and TSC-101 are the Company's two lead TCR-T therapy candidates for the treatment of heme malignancies. TScan has developed two lead TCR-T therapy candidates, TSC-100 and TSC-101, that target minor histocompatibility antigens HA-1 and HA-2, respectively.
BTIG Research initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $12.00
Needham initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $11.00
Wedbush initiated coverage of TScan Therapeutics with a rating of Outperform and set a new price target of $8.00